Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney

Svedman, Christer; Karlsson, Kristin; Rutkowska, Eva; Sandström, Per; Blomgren, Henric; Lax, Ingmar; Wersäll, Peter

doi:10.1080/02841860802123196

Cited by 89 publications

(45 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to other local therapeutic modalities, SBRT offers the only noninvasive, highly efficient means to eradicate discreet tumor foci either at a primary or metastatic site with radiobiologically potent dose . Table 1 shows the results of SBRT for primary and metastatic RCC (Wersall et al 2005;Svedman et al 2006;Nguyen et al 2010;Svedman et al 2008;Gerszten et al 2005;Beitler et al 2004;Ponsky et al 2007;Teh et al 2007a, b, c;Kaplan et al 2010;Zelefsky et al 2012;Jhaveri et al 2012). The reported results were encouraging.…”

Section: Clinical Application and Studiesmentioning

confidence: 56%

Renal Cell Carcinoma

Teh¹,

Ishiyama²,

Blanco³

et al. 2012

Stereotactic Body Radiation Therapy

View full text Add to dashboard Cite

Section: Clinical Application and Studiesmentioning

confidence: 56%

Renal Cell Carcinoma

Teh¹,

Ishiyama²,

Blanco³

et al. 2012

Stereotactic Body Radiation Therapy

View full text Add to dashboard Cite

“…In a study by Svedman and colleagues, 7 patients were treated with contralateral kidney metastases post-nephrectomy. 27 In this series, no significant renal dysfunction was observed; all patients had normal serum creatinine levels prior to SBRT, and only 2 of 7 developed a rise in creatinine that stabilized long term. In the series by Staehler and colleagues, the median creatinine clearance did not significantly change from pre-SBRT (76.8 mL/min) to post-SBRT levels (70.3 mL/min; p = 0.89).…”

Section: Kidney Toxicity Following Sbrtmentioning

confidence: 84%

“…20,21,[24][25][26][27][28][29] No randomized trials to date have evaluated SBRT in primary kidney cancer.…”

Section: Clinical Evidence Of Sbrt In Rccmentioning

confidence: 99%

Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions

Swaminath

Chu

2015

CUAJ

View full text Add to dashboard Cite

The incidence of renal cell carcinoma (RCC) is steadily rising due to an aging population and more frequent imaging of the abdomen for other medical conditions. While surgery remains the standard of care treatment for localized disease, many patients are unfit due to their advanced age and medical comorbidities. In these patients, an active surveillance strategy or ablative therapies, including radiofrequency/microwave ablation or cryotherapy, can be offered. Such options have limitations particularly with fast growing, or larger tumors. A promising ablative therapy option to consider is stereotactic body radiotherapy (SBRT). SBRT refers to high dose, focally ablative radiation delivered in a short time (3-5 fractions), and is safe and effective in many other cancer sites, including lung, liver and spine. SBRT offers potential advantages in the primary kidney cancer setting due to its ablative dosing (overcoming the notion of "radio-resistance"), short treatment duration (important in an elderly population), low toxicity profile (enabling SBRT to treat larger RCCs than other ablative modalities), and non-invasiveness. To date, there is limited long-term prospective data on the outcomes of SBRT in primary RCC. However, early evidence is intriguing with respect to excellent local control and low toxicity; however, most studies vary in terms of technique and radiation dosing used. Welldesigned prospective cohort studies with clearly defined and standardized techniques, dosing, follow-up, and integration of quality of life outcomes will be essential to further establish the role of SBRT in management of inoperable, localized RCC.

show abstract

“…Four patients developed transient grade 1-2 toxicity (nausea, fatigue, and local pain). None of the patients needed dialysis (Svedman et al 2008).…”

Section: Sbrt For Renal Cell Carcinomamentioning

confidence: 99%